US-LISTED biopharma-company Alexion has announced 97.7% of Wilson Therapeutics shareholders have accepted its offer to acquire the rare liver-disorder (Wilson Disease) therapy company.
The disease affects around one in every 30,000 people worldwide.
The above article was sent to subscribers in Pharmacy Daily's issue from 30 May 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 May 18
